A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis

Influence of dietary fat intake on the endocannabinoid system in lean and obese subjects

(2014) Stefan Engeli et al.   Obesity

Peripherally restricted CB1 receptor blockers

(2013) Robert J. Chorvat   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects

(2013) Linda E. Klumpers et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The Endocannabinoid System in Energy Homeostasis and the Etiopathology of Metabolic Disorders

(2013) Cristoforo Silvestri et al.   Cell Metabolism

The cannabinoid receptor 1 and its role in influencing peripheral metabolism

(2013) L. O'Keefe et al.   DIABETES OBESITY & METABOLISM

Adaptive thermogenesis in adipocytes: Is beige the new brown?

(2013) J. Wu et al.   GENES & DEVELOPMENT

Discovery of 1-(2,4-Dichlorophenyl)-N-(piperidin-1-yl)-4-((pyrrolidine-1-sulfonamido)methyl)-5-(5-((4-(trifluoromethyl)phenyl)ethynyl)thiophene-2-yl)-1H-pyrazole-3-carboxamide as a Novel Peripherally Restricted Cannabinoid-1 Receptor Antagonist with Significant Weight-Loss Efficacy in Diet-Induced Obese Mice

(2013) Chun-Ping Chang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes

(2013) Tony Jourdan et al.   NATURE MEDICINE

Peripheral Cannabinoid-1 Receptor Inverse Agonism Reduces Obesity by Reversing Leptin Resistance

(2012) Joseph Tam et al.   Cell Metabolism

Age-Related Impairment in Insulin Release: The Essential Role of  2-Adrenergic Receptor

(2012) G. Santulli et al.   DIABETES

Formoterol, a highly β2-selective agonist, increases energy expenditure and fat utilisation in men

(2012) P Lee et al.   INTERNATIONAL JOURNAL OF OBESITY

Cannabinoids Induce Pancreatic  -Cell Death by Directly Inhibiting Insulin Receptor Activation

(2012) W. Kim et al.   Science Signaling

β2-Adrenoceptors increase translocation of GLUT4 via GPCR kinase sites in the receptor C-terminal tail

(2011) Nodi Dehvari et al.   BRITISH JOURNAL OF PHARMACOLOGY

Induction of fatty acid oxidation resists weight gain, ameliorates hepatic steatosis and reduces cardiometabolic risk factors

(2011) R S Vijayakumar et al.   INTERNATIONAL JOURNAL OF OBESITY

Endocannabinoid signal in the gut controls dietary fat intake

(2011) N. V. DiPatrizio et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CB1 Signaling in Forebrain and Sympathetic Neurons Is a Key Determinant of Endocannabinoid Actions on Energy Balance

(2010) Carmelo Quarta et al.   Cell Metabolism

Discovery of 1-(2,4-Dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a Potential Peripheral Cannabinoid-1 Receptor Inverse Agonist

(2010) Ming-Shiu Hung et al.   ChemMedChem

Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity

(2010) Joseph Tam et al.   JOURNAL OF CLINICAL INVESTIGATION

Biphasic suppression of appetite by cannabinoid CB1 receptor antagonists with distinct functional activities

(2010) Yinchiu Lin et al.   PHARMACOLOGICAL RESEARCH

CB1 antagonists for obesity—what lessons have we learned from rimonabant?

(2009) Vincenzo Di Marzo et al.   Nature Reviews Endocrinology

Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice

(2008) Douglas Osei-Hyiaman et al.   JOURNAL OF CLINICAL INVESTIGATION

CB1 Receptor Blockade and its Impact on Cardiometabolic Risk Factors: Overview of the RIO Programme with Rimonabant

(2008) A. J. Scheen   JOURNAL OF NEUROENDOCRINOLOGY

Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets

(2008) Isabel Matias et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY